Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
Xiangpeng Dai(Beth Israel Deaconess Medical Center), Wenjian Gan(Beth Israel Deaconess Medical Center), Xiaoning Li(Beth Israel Deaconess Medical Center), Shangqian Wang(Memorial Sloan Kettering Cancer Center), Wei Zhang(Duke University), Ling Huang(Beth Israel Deaconess Medical Center), Shengwu Liu(Harvard University), Qing Zhong(University Hospital of Zurich), Jianping Guo(Beth Israel Deaconess Medical Center), Jinfang Zhang(Beth Israel Deaconess Medical Center), Ting Chen(Harvard University), Kouhei Shimizu(Beth Israel Deaconess Medical Center), Francisco Beça(Beth Israel Deaconess Medical Center), Mirjam Blattner(Cornell University), Divya Vasudevan(Cornell University), Dennis L. Buckley(Harvard University), Jun Qi(Harvard University), Lorenz Buser(University Hospital of Zurich), Pengda Liu(Beth Israel Deaconess Medical Center), Hiroyuki Inuzuka(Beth Israel Deaconess Medical Center), Andrew H. Beck(Beth Israel Deaconess Medical Center), Liewei Wang(Mayo Clinic), Peter J. Wild(University Hospital of Zurich), Levi A. Garraway(Harvard University), Mark A. Rubin(Cornell University), Christopher E. Barbieri(Cornell University), Kwok‐Kin Wong(Harvard University), Senthil K. Muthuswamy(Beth Israel Deaconess Medical Center), Jiaoti Huang(Duke University), Yu Chen(Memorial Sloan Kettering Cancer Center), James E. Bradner(Harvard University), Wenyi Wei(Beth Israel Deaconess Medical Center)
Cited by 340Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis